ClinicalTrials.gg
Active, not recruitingNCT02647099ALASCCAUpdated Mar 13, 2026Results posted

Adjuvant Low Dose Aspirin in Colorectal Cancer

A Phase 3 interventional study of Acetylsalicylic acid and Placebo in Colorectal Cancer, sponsored by Anna Martling. Active, not recruiting at 32 sites in 4 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-03-13.

Sponsored by Anna Martling · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
626
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies testing aspirin in Colorectal Neoplasms — 1 open to participants now, 9 under way, 5 of them phase 3. Aspirin · Colorectal Neoplasms.

Enrollment
7th of 22
626 · median 161
Started
2016
the only one that year
Phase 3
7 of 22
none open now
Registered
11th of 22
by date
Lead sponsor
1 of 22
Anna Martling

Among the 22 studies testing aspirin in Colorectal Neoplasms, this one is the 7th largest by enrollment, is the only one that started in 2016, is one of 7 in phase 3, and was the 11th registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

1 of the 22 studies testing aspirin in Colorectal Neoplasms is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About aspirin

Aspirin: first FDA approval 1950 (PERCODAN), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing aspirin in Colorectal Neoplasms, or all of them as a file.
02

Study summary

ALASCCA is a randomized, parallel group, double blind, multicenter, placebo-controlled, biomarker-based study of adjuvant treatment with low dose aspirin in patients with colorectal cancer. Hypothesis is that patients diagnosed with colorectal cancer and somatic mutations in PI3K pathway can significantly improve survival if treated with low dose aspirin.

Read the detailed description

Patients with colorectal cancer clinical stage I-III will be screened for inclusion at the time of tumor surgery (at time of routine patient visit before elective surgery or postoperatively within 12 weeks in case of emergency procedure or if screening was missed preoperatively). After inclusion and when surgery is performed, patients with PIK3 mutations and stage II and III tumors will be randomized to receive 160 mg aspirin or placebo orally.

Last date for randomization and start of treatment is 12 weeks postoperatively. The treatment can be administered alone or in combination with adjuvant chemotherapy. The choice of any adjuvant chemotherapy is made by the Investigator and should follow the guidelines in the National Care Program. The treatment will be administered for 3 years. There will be a follow-up period for two years. Outside the trial, the patient will be treated according to standard care at the site.

A phone contact will be made 3 months after the randomization visit and thereafter every 6th month. The patients will also visit the site 6 months after randomization and thereafter every 6th month i.e. the patients will be in contact with the site every 3rd month. There will also be a visit/phone contact at the end of the follow-up period.

The primary objective is to determine whether adjuvant treatment with 160mg ASA once daily for 3 years can improve time to recurrence in participants with colorectal cancer with somatic alternations in the PI3K singling pathway.

UPDATE: New dimensional analysis and power calculation, 19th October 2020:

A total of 3900 patients will be screened in order to include 300 patients with PIK3CA (Exon 9 and 20) mutated tumors in each treatment arm (Group A). With an estimated 10 % drop-out rate, 150 patients will be randomized in each arm. This also includes approximately 15 % of the patients that will be excluded due to tumor stage 1.

An additional 300 patients with mutations in other PI3K pathway genes PIK3CA (other than exon 9 and 20), PIK3R1 or PTEN will also be randomized in each arm and will be treated as a separate group in the analyses (Group B). With an estimated 10 % drop-out rate, 150 patients will be randomized in each arm.

Patients already treated with ASA at inclusion will be included in an observation group.

An interim analysis will be made on safety i.e incidence and type of serious bleeding complication grade > 1 after 12 months. An independent safety data monitoring committee will be responsible for evaluating and follow-up of the safety.

03

Conditions studied

  • Colorectal Cancer

Keywords

  • Aspirin
  • PI3K signaling pathway
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Tumor with somatic alterations in PIK3CA, PIK3R1 or PTEN
  • Colon or rectal cancer tumor stage II-III
  • Radical surgery according to surgeon and pathologist
  • performance status ≥60%
  • ≥ 100 x 109 / L
  • Clean Colonoscopy or Computed Tomography (CT) colon within 3 months preoperatively or postoperatively but before randomization
  • Patient able to swallow tablets
  • Patient able to understand and sign written

Exclusion criteria

Exclusion Criteria:

  • Hereditary colorectal cancer linked to familial colonic polyposis or Lynch syndrome
  • Inflammatory bowel disease (Crohn's disease or ulcerative colitis)
  • Distant
  • Other cancers (excluding colorectal cancer or other skin cancer than melanoma) within 3 years from screening
  • Known bleeding diathesis (such as hemophilia)
  • Concomitant antiplatelet therapy (eg clopidrogrel or ticlopidine) or anticoagulant therapy (warfarin or low molecular weight heparin). Post-operative treatment with low molecular weight heparin must be withdrawn before administration of study treatment
  • Active gastritis or peptic ulcer, or significant surgical post-op bleeding, within the previous three months assessed at screening and randomization
  • Ongoing regular use of , Nonsteroidal Anti-Inflammatory Drug (NSAID)
  • Uncontrolled hypertension according to Investigator's judgment
  • liver impairment according to Investigators judgment
  • Existing renal failure according to Investigator's judgment. Renal failure with decreased \<60 should lead to consultation with a nephrologist.
  • Significant medical illness that would interfere with study participation
  • Pregnancy or breastfeeding females
  • Known allergy to NSAIDs or ASA
  • Current participation in another clinical trial that will be in conflict with the present study
  • Patients who are unlikely to comply with the protocol (e.g. uncooperative attitude, inability to return for subsequent visits) and/or otherwise considered by the Investigator to be unlikely to complete the study
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
626 participants (actual)

Study arms

  • Active comparator
    Aspirin

    One tablet acetylsalicylic acid (ASA) 160 mg, orally once daily for three years

    Drug: Acetylsalicylic acid

  • Placebo comparator
    Placebo

    One tablet placebo orally once daily for three years

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Time To Recurrence (TTR)

    Number of participants with local recurrence, distant metastases or death from same cancer within 3 years from randomization

    Time frame: 3 years

Secondary outcomes

  1. Disease Free Survival (DFS)

    Number of participants with local recurrence, distant metastases, a new malignant neoplasm, or death from any cause within 3 years from randomization

    Time frame: 3 years

  2. Overall Survival (OS)

    Death from any cause within 5 years from randomization

    Time frame: 5 years

  3. Frequency and Severity of Adverse Events (AE)

    The frequency and severity of severe adverse events in the safety population

    Time frame: 1 year and 3 years

07

Results

Posted Mar 13, 2026

Participant flow

First patient initial screening April 6, 2016. Last patient initial screening April 28, 2021. First patient randomized April 7, 2016. Last patient randomized July 19, 2021.

Participant flow — Overall Study
MilestoneAspirinPlacebo
Started313313
Completed311312
Not completed21
Withdrew: Lost to follow-up21

Outcome measures

PrimaryTime To Recurrence (TTR)

Number of participants with local recurrence, distant metastases or death from same cancer within 3 years from randomization

Time frame:
3 years
Reported as:
Count of participants · Participants
Time To Recurrence (TTR)
ParticipantsAspirinPlacebo
Time To Recurrence (TTR)2450
Statistical analysis
  • Aspirin vs Placebo · Regression, Cox · p = 0.00138 (P-value from Cox proportional Hazards Model comparing time to recurrence within 3 years between patients randomized to aspirin and patients randomized to placebo.) · Hazard ratio (hr): 0.45 · 95% CI 0.28 to 0.74
SecondaryDisease Free Survival (DFS)

Number of participants with local recurrence, distant metastases, a new malignant neoplasm, or death from any cause within 3 years from randomization

Time frame:
3 years
Reported as:
Count of participants · Participants
Disease Free Survival (DFS)
ParticipantsAspirinPlacebo
Disease Free Survival (DFS)3865
Statistical analysis
  • Aspirin vs Placebo · Regression, Cox · p = 0.0036 · Hazard ratio (hr): 0.55 · 95% CI 0.37 to 0.82
SecondaryOverall Survival (OS)

Death from any cause within 5 years from randomization

Time frame:
5 years

Results for this outcome have not been posted.

SecondaryFrequency and Severity of Adverse Events (AE)

The frequency and severity of severe adverse events in the safety population

Time frame:
1 year and 3 years
Reported as:
Count of participants · Participants
Frequency and Severity of Adverse Events (AE)
ParticipantsAspirinPlacebo
Severe adverse events5236
Non-severe adverse events134110

Adverse events

Collected over From the date when a participant first received the study drug until end of follow-up (maximum 3 years from randomization), or until an outcome (recurrence/death), or until the participant dropped out of the trial.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Aspirin25/309 (8.1%)52/309 (16.8%)134/309 (43.4%)
Placebo32/311 (10.3%)36/311 (11.6%)110/311 (35.4%)
Most frequent serious events
Showing 10 of 41
Most frequent serious events
EventAspirinPlacebo
IleusGastrointestinal disorders11/3092/311
Deep vein thrombosisVascular disorders9/3097/311
Pulmonary embolismVascular disorders4/3093/311
InjuryInjury, poisoning and procedural complications1/3093/311
Covid-19 infectionInfections and infestations2/3090/311
Death, unknown causeGeneral disorders2/3090/311
Ischemic strokeVascular disorders2/3090/311
Parastomal herniaGastrointestinal disorders2/3090/311
CholecystitisHepatobiliary disorders1/3092/311
Urinary tract infectionInfections and infestations1/3092/311
Most frequent other events
Most frequent other events
EventAspirinPlacebo
Adverse event of the gastrointestinal organ systemGastrointestinal disorders52/30949/311
Adverse event of the hematologic organ systemBlood and lymphatic system disorders51/30933/311
Adverse event of the skinSkin and subcutaneous tissue disorders20/30918/311
Musculoskeletal and Connective Tissue DisordersMusculoskeletal and connective tissue disorders18/30920/311

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)AspirinPlaceboTotal
<=18 years000
Between 18 and 65 years147140287
>=65 years166173339
Sex: Female, Male
Sex: Female, Male(Participants)AspirinPlaceboTotal
Female164160324
Male149153302
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)AspirinPlaceboTotal
Count of participants——0
Region of Enrollment
Region of Enrollment(Participants)AspirinPlaceboTotal
Sweden244245489
Norway323769
Denmark191433
Finland181735
Tumour location
Tumour location(Participants)AspirinPlaceboTotal
Right colon137142279
Left colon7166137
Colon (side not specified)123
Rectum104103207
Somatic alteration
Somatic alteration(Participants)AspirinPlaceboTotal
PIK3CA exon 9/20 hotspot mutations157157314
Other PI3K alterations156156312
08

Study locations

32 sites
09

References and documents

Publications

  • Martling A, Hed Myrberg I, Nilbert M, Gronberg H, Granath F, Eklund M, Oresland T, Iversen LH, Haapamaki C, Janson M, Westberg K, Segelman J, Ersson U, Prytz M, Angenete E, Bergstrom R, Mayrhofer M, Glimelius B, Lindberg J; ALASCCA Study Group. Low-Dose Aspirin for PI3K-Altered Localized Colorectal Cancer. N Engl J Med. 2025 Sep 18;393(11):1051-1064. doi: 10.1056/NEJMoa2504650. PubMed 40961426 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2016 to primary completion in Aug 2024, 100 months.

Results were first posted in Mar 2026, 1 year 7 months after primary completion.

Of 106 non-industry phase 3 interventional studies under Colorectal Neoplasms, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 116. This study's 100 months is above that.

Counting every sponsor, half of 175 studies reached it within 50 months; a quarter within 35 and three quarters within 79.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2016
First posted
Jan 6, 2016
StartActual
Apr 7, 2016
Primary completionActual
Aug 2024
CompletionEst.
Aug 2026
Results first posted
Mar 13, 2026
Last update
Mar 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02647099
Lead sponsor
Anna Martling
Collaborators
Uppsala University Hospital, Skane University Hospital
Responsible party
Anna Martling (Professor, Karolinska Institutet) — Sponsor-investigator
First posted
Jan 6, 2016
Start date
Apr 7, 2016
Primary completion
Aug 2024
Completion
Aug 2026 (estimated)
Results posted
Mar 13, 2026
Last update
Mar 13, 2026

Study contacts

Anna Martling, Professor
principal investigator · Karolinska Institutet

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aspirin

Start the discussion